Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RLYB116 in Healthy Participants

X
Trial Profile

Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RLYB116 in Healthy Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RLYB 116 (Primary)
  • Indications Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Dec 2023 Interim results presented in a Rallybio Media Release.
    • 03 Sep 2023 According to a Rallybio media release, based data from this trial the company will disclose indication strategy for RLYB116 in the fourth quarter of 2023.
    • 03 Sep 2023 According to a Rallybio media release, the company presented a poster of this study at the 29th International Complement Workshop (ICW), in Newcastle, UK.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top